Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug 30;3(5):404-406.
doi: 10.1016/j.jdcr.2017.06.004. eCollection 2017 Sep.

Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy

Kelsey Hirotsu  1 , Albert S Chiou  1 , Audris Chiang  2 , Jinah Kim  1 , Bernice Y Kwong  1 , Silvina Pugliese  1
Affiliations
Case Reports

Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy

Kelsey Hirotsu et al. JAAD Case Rep. .
No abstract available

Keywords: BP, bullous pemphigoid; PD-1, programmed cell-death receptor 1; bullous pemphigoid; programmed cell death receptor 1 inhibition; radiation.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Clinical photograph of tense bullae localized to irradiated skin after anti–PD-1 therapy and radiation for in-transit cutaneous metastases to the thigh.
Fig 2
Fig 2
Hematoxylin-eosin staining (A) and direct immunofluorescence on salt-split perilesional skin biopsy (B), both 100×-hematoxylin-eosin. Microscopic examination found subepidermal blister formation with numerous eosinophils in the blister cavity and a superficial dermal infiltrate consisting primarily of eosinophils. Periodic acid–Schiff stain was negative. Direct immunofluorescence studies on salt-split showed 2+ linear staining of IgG at the dermoepidermal junction.
See this image and copyright information in PMC

References

    1. Hwang S.J., Carlos G., Chou S., Wakade D., Carlino M.S., Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res. 2016;26(4):413–416. - PubMed
    1. Naidoo J., Schindler K., Querfeld C. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383–389. - PMC - PubMed
    1. Damsky W., Kole L., Tomayko M.M. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep. 2016;2(6):442–444. - PMC - PubMed
    1. Jour G., Glitza I.C., Ellis R.M. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688–696. - PubMed
    1. Kwon C.W., Land A.S., Smoller B.R., Scott G., Beck L.A., Mercurio M.G. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor. J Eur Acad Dermatol Venereol. 2017 [Epub ahead of print] - PubMed

Publication types

LinkOut - more resources